The combination of T-DM1 and osimertinib in patients with EGFR-mutated NSCLC who had progressed on prior EGFR-tyrosine kinase inhibitor (TKI) therapy, including osimertinib, demonstrated a favourable safety profile, albeit with limited clinical efficacy [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.